Dexcom’s new CEO is eyeing growth in the international market as a key strategy for 2026, fresh off the back of the company ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

DexCom, Inc. DXCM reported strong preliminary results for the fourth quarter and full-year 2025. Despite the robust ...

DexCom, Inc. , the global leader in glucose biosensing, is ushering in the next era of transformative, customer-driven innovation under the leadership of President and CEO Jake Leach, who assumed his ...

DexCom overview and recent share performance DexCom (DXCM) has drawn fresh attention as investors reassess its continuous glucose monitoring business and recent share performance, with the stock last ...

DexCom will release its fourth-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, which was up from ...

There are exciting advancements in patient standard of care thanks to continuous health monitoring technologies.

Diabeloop receives FDA 510(k) clearance for DBLG2, an Automated Insulin Delivery algorithm in an App: a strategic ...

A new real-world retrospective analysis published in Diabetes Care showed that users of the MiniMedtm 780G system achieved American Diabetes Association (ADA) recommended goals for time-in-range (TIR) ...

Read our live updates from CES 2026 in Las Vegas to see the latest consumer gadgetry in all of its chatbot-enabled, ...

Diabeloop receives US FDA 510(k) clearance for DBLG2, an automated insulin delivery algorithm: Grenoble, France Saturday, January 10, 2026, 10:00 Hrs [IST] Diabeloop, a global com ...